- Home
- CAPR vs NECB Comparison
CAPR vs NECB Comparison
Compare CAPR & NECB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPR
- NECB
- Stock Information
- Founded
- CAPR 2005
- NECB 1934
- Country
- CAPR United States
- NECB United States
- Employees
- CAPR N/A
- NECB N/A
- Industry
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- NECB Savings Institutions
- Sector
- CAPR Health Care
- NECB Finance
- Exchange
- CAPR Nasdaq
- NECB Nasdaq
- Market Cap
- CAPR 324.6M
- NECB 282.4M
- IPO Year
- CAPR N/A
- NECB N/A
- Fundamental
- Price
- CAPR $4.66
- NECB $20.33
- Analyst Decision
- CAPR Strong Buy
- NECB
- Analyst Count
- CAPR 6
- NECB 0
- Target Price
- CAPR $23.17
- NECB N/A
- AVG Volume (30 Days)
- CAPR 1.9M
- NECB 46.4K
- Earning Date
- CAPR 11-10-2025
- NECB 10-23-2025
- Dividend Yield
- CAPR N/A
- NECB 4.91%
- EPS Growth
- CAPR N/A
- NECB N/A
- EPS
- CAPR N/A
- NECB 3.21
- Revenue
- CAPR $11,130,509.00
- NECB $102,569,000.00
- Revenue This Year
- CAPR N/A
- NECB $1.90
- Revenue Next Year
- CAPR $7,894.07
- NECB $6.93
- P/E Ratio
- CAPR N/A
- NECB $6.34
- Revenue Growth
- CAPR N/A
- NECB N/A
- 52 Week Low
- CAPR $4.40
- NECB $19.27
- 52 Week High
- CAPR $20.75
- NECB $31.72
- Technical
- Relative Strength Index (RSI)
- CAPR 31.84
- NECB 54.06
- Support Level
- CAPR $5.52
- NECB $19.39
- Resistance Level
- CAPR $6.01
- NECB $20.50
- Average True Range (ATR)
- CAPR 0.49
- NECB 0.53
- MACD
- CAPR -0.06
- NECB 0.05
- Stochastic Oscillator
- CAPR 12.42
- NECB 87.73
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
About NECB NorthEast Community Bancorp Inc.
NorthEast Community Bancorp Inc operates as a community-oriented financial institution. It is principally engaged in the business of attracting deposits and investing those funds into mortgage and commercial loans. It conducts activities throughout the Northeastern United States including New York, Massachusetts, New Jersey, and Connecticut. The company offers a comprehensive line of banking products and services, including mobile banking as well as commercial real estate loans, commercial construction financing, lines of credit, and term loans. It also offers investment advisory and financial planning services.